

Innovative BioMedical Devices

Unit 9, 589 Stirling Highway
bioMD Limited ABN 35 088 221 078
Cottesloe, Western Australia 6011
PO Box 956, Cottesloe
Western Australia 6911

Telephone (08) 9385 5038
Facsimile (08) 9385 5028

www.biomd.com.au

Announcement to the Australian Stock Exchange

8 February 2011

Company Announcements Office
Australian Stock Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

Southern Cross Equities – Biotech Round Up *“Biotech, pharmaceuticals and medical devices”*

bioMD Limited (ASX: BOD) is pleased direct its shareholders and the market to the Company’s website to view research coverage by Southern Cross Equities Limited Incorporated.

http://www.biomd.com.au/invest_research.asp

This follows earlier research coverage by Southern Cross Equities Limited Incorporated released on 2 March 2010, which can also be found on bioMD’s website.

About bioMD Limited

bioMD (ASX: BOD) is an Australian company commercialising innovative tissue engineering technology for use in cardiothoracic and abdominal surgery. The ADAPT technology offers significant improvements to current tissue processing technologies in terms of immunogenicity and tissue durability. Its lead product, CardioCel, continues to be evaluated in a Phase II human trial in South Africa for various cardiac repair procedures. bioMD is currently maximising shareholder value via pursuit of corporate partnerships, successful completion of clinical milestones and rapid commercialisation strategies.

About the ADAPT Tissue Engineering Process

ADAPT Tissue Engineering Process (TEP) produces a bioprosthetic scaffold (extracellular matrix) made from animal tissue. Depending on the site of implantation, the patient's own cells will migrate into the matrix and stimulate site specific controlled remodelling. At the same time, new blood vessels are formed in the matrix and they deliver appropriate cells that lead to a functional tissue repair. The implanted extracellular matrix is gradually remodelled and replaced by the body’s own new tissue structures.

For more information, please contact:

Michael Bennett – Managing Director Tel +61 8 9385 5038 or 0419 944 567
Robert Towner - Executive Director Tel: +61 8 9286 2828 or 0414 594 868